Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy

Hadji, Peyman; Ziller, M.; Kieback, Dirk G.; Dornoff, W.; Tessen, H.W.; Menschik, Thomas; Kuck, Joachim; Melchert, F.; Hasenburg, Annette

doi:10.1093/annonc/mdn762

Cited by 61 publications

(36 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TEAM Germany reported lumbar spine and femoral BMDs significantly increased in tamoxifen patients at 1 year of treatment compared with exemestane patients [19]. Similarly, TEAM United States showed lumbar spine and femoral BMDs decreased by 0.4 and 0.7% in tamoxifen patients and by 3.0 and 2.5% in exemestane patients at 2 years of treatment [20].…”

Section: Discussionmentioning

confidence: 99%

Effects of Exemestane, Anastrozole and Tamoxifen on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Early Breast Cancer Patients: Results of N-SAS BC 04, the TEAM Japan Substudy

Aihara

Suemasu²,

Takei³

et al. 2010

Oncology

View full text Add to dashboard Cite

Background: Use of aromatase inhibitors in women with postmenopausal breast cancer accompanies risks of bone loss. We evaluated changes in bone mineral density (BMD) and bone turnover markers in patients treated with exemestane, anastrozole or tamoxifen for hormone-sensitive postmenopausal early breast cancer. Patients and Methods: Sixty-eight patients enrolled in the Tamoxifen Exemestane Adjuvant Multinational Japan bone substudy were randomly assigned to receive tamoxifen, exemestane or anastrozole. During a 2-year study period, lumbar spine BMD was measured using dual-energy X-ray absorptiometry, and urinary type I collagen cross-linked N-telopeptide (NTX) and serum bone-specific alkaline phosphatase (BAP) were also measured. Results: BMD at 2 years of treatment was higher in tamoxifen patients compared with exemestane and anastrozole patients; however, the intergroup difference was not significant (p = 0.2521 and p = 0.0753, respectively). BMD was higher in exemestane patients compared with anastrozole patients; however, the intergroup difference was not significant (p = 0.7059 and p = 0.8134, respectively). NTX and BAP were significantly lower in tamoxifen patients compared with exemestane and anastrozole patients at 1 and 2 years of treatment (p < 0.05). Conclusion: Tamoxifen may provide better bone protection compared with exemestane or anastrozole. The effect of exemestane and anastrozole on bone loss may be comparable in Japanese postmenopausal women.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Exemestane, Anastrozole and Tamoxifen on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Early Breast Cancer Patients: Results of N-SAS BC 04, the TEAM Japan Substudy

Aihara

Suemasu²,

Takei³

et al. 2010

Oncology

View full text Add to dashboard Cite

show abstract

“…Methodologies for each sub-study have been reported previously (Hadji et al 2009a;Jones et al 2008a;van Nes et al 2008).…”

Section: Methodsmentioning

confidence: 99%

The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies

Hadji

Asmar²,

Nes

et al. 2010

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…In the TEAM trial, tamoxifen treatment resulted in a 0.5% increase from baseline in BMD at the spine, which was maintained at 12 months assessment (n = 83). In contrast, exemestane treatment resulted in an increase in bone loss at 6 months (2.6% decrease in spine BMD), and a further decrease of 0.2% at 12 months analysis (n = 78) [32]. In a recent subanalysis of the TEAM trial, exemestane resulted in increases from baseline in all bone turnover marker levels (e.g.…”

Section: Exemestanementioning

confidence: 96%

Guidelines for Osteoprotection in Breast Cancer Patients on an Aromatase Inhibitor

Hadji¹

2010

Breast Care

View full text Add to dashboard Cite

show abstract

Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy

Abstract: Exemestane treatment resulted in an increase in bone loss at 6 months; bone loss stabilised after 6- to 12-month treatment.

Cited by 61 publications

References 29 publications

Effects of Exemestane, Anastrozole and Tamoxifen on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Early Breast Cancer Patients: Results of N-SAS BC 04, the TEAM Japan Substudy

Effects of Exemestane, Anastrozole and Tamoxifen on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Early Breast Cancer Patients: Results of N-SAS BC 04, the TEAM Japan Substudy

The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies

Guidelines for Osteoprotection in Breast Cancer Patients on an Aromatase Inhibitor

Contact Info

Product

Resources

About